Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 3841 - 3848 of 12007 results
TCPA Regulatory Update — FCC Adopts Safe Harbor to Encourage Blocking of Unwanted Robocalls; FCC Releases TCPA Clarifications & Updates
July 27, 2020| Article| Viewpoint
Federal Circuit: Licensees’ Failure to Mark Eliminates Entitlement to Pre-Suit Damages
July 27, 2020| Blog| Viewpoint
Remedies for Trade Secret Misappropriation
July 27, 2020| Video| Viewpoint
Introduction to the Due Diligence Process
July 27, 2020| News
Department of Homeland Security Lifts Suspension of Trusted Traveler Enrollment for New York Residents
July 27, 2020| Blog| Viewpoint
Energy & Sustainability Washington Updates – August 2020
July 27, 2020| Article| Viewpoint
The Future of Telehealth
July 24, 2020| Video| Viewpoint
Beyond COVID: House Committee Advances Several FDA-Related Bills
July 23, 2020| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|